Effect of serotype 5 adenoviral and serotype 2 adeno-associated viral vector-mediated gene transfer to salivary glands on the composition of saliva

Jianghua Wang, Antonis Voutetakis, Fumi Mineshiba, Gabor G. Illei, Howard Dang, Chih-ko Yeh, Bruce J. Baum

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Key to the development of a useful clinical therapy is the minimization of side effects. Routine safety testing, however, does not provide information about the physiological status of many potentially useful gene transfer target sites. In this study, we evaluated the longitudinal effects of intrasalivary duct delivery of recombinant serotype S adenoviral (rAd5; 109-10 10 particles/gland in rats) and recombinant serotype 2 adeno-associated viral (rAAV2; 108-109 particles/gland in mice) vectors on salivary composition. Both vectors led to modest, transient alterations in several salivary components that thereafter returned to normal. The changes suggested two initial specific consequences of rAd5 and rAAV2 vector administration: (1) a modest breach of the mucosal barrier in the targeted glands, indicated by elevations in salivary albumin, total protein, and Na + levels, and (2) an innate host response, indicated by transient elevations in either salivary lactoferrin and IgA levels (rAd5) or mucin (rAAV2). These studies are consistent with the notion that administration of modest doses of rAd5 and rAAV2 vectors to salivary glands for a therapeutic purpose can be accomplished without severe or permanent injury to the target tissue, or compromise to its essential exocrine physiological function.

Original languageEnglish (US)
Pages (from-to)455-463
Number of pages9
JournalHuman Gene Therapy
Volume17
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Salivary Glands
Saliva
Lactoferrin
Mucins
Immunoglobulin A
Genes
Albumins
Safety
Wounds and Injuries
Therapeutics
Proteins
Serogroup

ASJC Scopus subject areas

  • Genetics

Cite this

Effect of serotype 5 adenoviral and serotype 2 adeno-associated viral vector-mediated gene transfer to salivary glands on the composition of saliva. / Wang, Jianghua; Voutetakis, Antonis; Mineshiba, Fumi; Illei, Gabor G.; Dang, Howard; Yeh, Chih-ko; Baum, Bruce J.

In: Human Gene Therapy, Vol. 17, No. 4, 04.2006, p. 455-463.

Research output: Contribution to journalArticle

Wang, Jianghua ; Voutetakis, Antonis ; Mineshiba, Fumi ; Illei, Gabor G. ; Dang, Howard ; Yeh, Chih-ko ; Baum, Bruce J. / Effect of serotype 5 adenoviral and serotype 2 adeno-associated viral vector-mediated gene transfer to salivary glands on the composition of saliva. In: Human Gene Therapy. 2006 ; Vol. 17, No. 4. pp. 455-463.
@article{6e96c0fecba846919a230181052cf800,
title = "Effect of serotype 5 adenoviral and serotype 2 adeno-associated viral vector-mediated gene transfer to salivary glands on the composition of saliva",
abstract = "Key to the development of a useful clinical therapy is the minimization of side effects. Routine safety testing, however, does not provide information about the physiological status of many potentially useful gene transfer target sites. In this study, we evaluated the longitudinal effects of intrasalivary duct delivery of recombinant serotype S adenoviral (rAd5; 109-10 10 particles/gland in rats) and recombinant serotype 2 adeno-associated viral (rAAV2; 108-109 particles/gland in mice) vectors on salivary composition. Both vectors led to modest, transient alterations in several salivary components that thereafter returned to normal. The changes suggested two initial specific consequences of rAd5 and rAAV2 vector administration: (1) a modest breach of the mucosal barrier in the targeted glands, indicated by elevations in salivary albumin, total protein, and Na + levels, and (2) an innate host response, indicated by transient elevations in either salivary lactoferrin and IgA levels (rAd5) or mucin (rAAV2). These studies are consistent with the notion that administration of modest doses of rAd5 and rAAV2 vectors to salivary glands for a therapeutic purpose can be accomplished without severe or permanent injury to the target tissue, or compromise to its essential exocrine physiological function.",
author = "Jianghua Wang and Antonis Voutetakis and Fumi Mineshiba and Illei, {Gabor G.} and Howard Dang and Chih-ko Yeh and Baum, {Bruce J.}",
year = "2006",
month = "4",
doi = "10.1089/hum.2006.17.455",
language = "English (US)",
volume = "17",
pages = "455--463",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of serotype 5 adenoviral and serotype 2 adeno-associated viral vector-mediated gene transfer to salivary glands on the composition of saliva

AU - Wang, Jianghua

AU - Voutetakis, Antonis

AU - Mineshiba, Fumi

AU - Illei, Gabor G.

AU - Dang, Howard

AU - Yeh, Chih-ko

AU - Baum, Bruce J.

PY - 2006/4

Y1 - 2006/4

N2 - Key to the development of a useful clinical therapy is the minimization of side effects. Routine safety testing, however, does not provide information about the physiological status of many potentially useful gene transfer target sites. In this study, we evaluated the longitudinal effects of intrasalivary duct delivery of recombinant serotype S adenoviral (rAd5; 109-10 10 particles/gland in rats) and recombinant serotype 2 adeno-associated viral (rAAV2; 108-109 particles/gland in mice) vectors on salivary composition. Both vectors led to modest, transient alterations in several salivary components that thereafter returned to normal. The changes suggested two initial specific consequences of rAd5 and rAAV2 vector administration: (1) a modest breach of the mucosal barrier in the targeted glands, indicated by elevations in salivary albumin, total protein, and Na + levels, and (2) an innate host response, indicated by transient elevations in either salivary lactoferrin and IgA levels (rAd5) or mucin (rAAV2). These studies are consistent with the notion that administration of modest doses of rAd5 and rAAV2 vectors to salivary glands for a therapeutic purpose can be accomplished without severe or permanent injury to the target tissue, or compromise to its essential exocrine physiological function.

AB - Key to the development of a useful clinical therapy is the minimization of side effects. Routine safety testing, however, does not provide information about the physiological status of many potentially useful gene transfer target sites. In this study, we evaluated the longitudinal effects of intrasalivary duct delivery of recombinant serotype S adenoviral (rAd5; 109-10 10 particles/gland in rats) and recombinant serotype 2 adeno-associated viral (rAAV2; 108-109 particles/gland in mice) vectors on salivary composition. Both vectors led to modest, transient alterations in several salivary components that thereafter returned to normal. The changes suggested two initial specific consequences of rAd5 and rAAV2 vector administration: (1) a modest breach of the mucosal barrier in the targeted glands, indicated by elevations in salivary albumin, total protein, and Na + levels, and (2) an innate host response, indicated by transient elevations in either salivary lactoferrin and IgA levels (rAd5) or mucin (rAAV2). These studies are consistent with the notion that administration of modest doses of rAd5 and rAAV2 vectors to salivary glands for a therapeutic purpose can be accomplished without severe or permanent injury to the target tissue, or compromise to its essential exocrine physiological function.

UR - http://www.scopus.com/inward/record.url?scp=33645916401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645916401&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.455

DO - 10.1089/hum.2006.17.455

M3 - Article

C2 - 16610933

AN - SCOPUS:33645916401

VL - 17

SP - 455

EP - 463

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 4

ER -